Full Archive
A recent study looked at the body’s immune system and how it responds to pleural mesothelioma, a cancer of the lining of the lungs. Results were published in the journal Pathobiology. The immune cells around the tumor area of 60 pleural mesothelioma patients were studied. The researchers used biomarkers to determine cell types and their…
Primary Outcome Measures Number of participants treated with Alintegimod monotherapy with treatment related adverse events as assessed by CTCAEv5.0 Number of participants treated with Alintegimod in combination with treatment related adverse events as assessed by CTCAEv5.0 Define RPTDs for Alintegimod Secondary Outcome Measures Characterize Pharmacokinetics of Alintegimod monotherapy by measuring Maximum Plasma Concentration (Cmax) Characterize…
Mesothelioma is a tough cancer to live with that is incurable and caused by asbestos. A recent study published in the European Journal of Oncology Nursing looked at the impact of mesothelioma on mental health and wellbeing. The frequency of mental health conditions among patients and caregivers was also examined. The study involved a survey…
This study is an open-label Phase Ib (Part A) dose escalation followed by a blinded, randomized, multi cohort Phase 2a (Part B) comparison of combination vs. reference regimens.
Currently study will only be enrolling the Phase 1b and the Phase 2a protocol requirements will be added to the study near completion of the Phase 1b
In a study presented today at the American Association for Cancer Research Annual Meeting 2024, researchers at Fox Chase Cancer Center showed that mice with a BAP1 germline mutation, after exposure to small levels of asbestos, had a greater chance of developing malignant mesothelioma. The study is being published in Cancer Research Communications, a journal…
Malignant mesothelioma is a hard cancer to treat and is mainly caused by asbestos. It was widely used in construction, steel mills, and other industries. Mesothelioma is especially hard to treat because it grows and spreads quickly. There are unfortunately not many options for the treatment of mesothelioma. It takes a long time for the…
This is a first in human (FIH) 2-part study using ACTM-838 in patients with advanced solid tumors resistant to standard of care treatment. Part 1a will evaluate dose escalation and Part 1b will evaluate dose expansion.
Mesothelioma is a hard cancer to treat that has low survival rates. This makes it a problem for doctors and researchers. A new study is looking to change this by looking at the collagen receptor uPARAP. The current clinical trial is looking at uPARAP, a protein that is found in higher levels in mesothelioma cells.…
In this Phase-II study, the investigators will investigate the efficacy and safety of lenvatinib in combination with pembrolizumab and chemotherapy in patients with malignant pleural mesothelioma.
New treatments and technologies offer hope for mesothelioma patients. One technology, 3D printing and optical scanning, has the potential to help those suffering with mesothelioma. The technologies refine and enhance what is known as photodynamic therapy, a promising new approach for the management of mesothelioma. Photodynamic therapy is a unique treatment that uses light to…
